Mission

Mission

The EDNSG is a study group of the European Association for the Study of Diabetes (EASD)
with special responsibility for Diabetic Nephropathy.

The aim of the EDNSG is to assemble researchers interested in diabetic renal disease in order to study epidemiology, pathology, pathophysiology and treatment of this complication of diabetes mellitus.

The ultimate goal of the EDNSG is to prevent the appearance or the development of kidney disease and to search for
the best treatment of this condition in diabetic patients.

Executive committee

Sally Marshall

Sally Marshall

President, UK

Samy Hadjadj

Samy Hadjadj

Vice-president, France

Daniel Gordin

Daniel Gordin

Secretary, Finland

Niina Sandholm

Niina Sandholm

Treasurer, Finland

Past meetings of EDNSG

1988 Pisa, Italy – U. Di Mario, R. Navalesi, R. Nosadini
1989 Aarhus, Denmark – C.E. Mogensen, J. Sandahl Christiansen,
1990 London, UK – G.C. Viberti
1991 Angers, France – M. Marre
1992 Helsinki, Finland – L. Groop, A. Ekstrand, C. Forsblom, C. Grönhagen-Riska
1993 Athens, Greece – B. Karamanos, P. Kontessis, A. Kofinis
1994 Zwolle, The Netherlands – E. van Ballegooie, H.J.G. Bilo
1995 Heidelberg, Germany – C. Hasslacher, H.P. Kempe
1996 Parma, Italy – A. Gnudi, R. Lugari
1997 Bratislava, Slovakia – P. Pontuch, V. Mojto, S. Kozáková
1998 Rennes, France – J-Y. Poirier, A. Moisan
1999 Gdańsk, Poland – E. Semetkowska-Jurkiewicz, E. Orlowska-Kunikowska

2000 Lund, Sweden – O. Torffvit
2001 County Durham, UK – R. Bilous, S. Marshall
2002 Barcelona, Spain – J.M. Mauri, J.M. Fernández Real, M.T. Gonzáles,
A.M. Castelao, R. Pascual, 2003 Elsinore, Denmark – H-H. Parving, L. Tarnow
2004 Bergamo, Italy – R. Trevisan
2005 Arnhem, The Netherlands – J.H.M. Berden, H.J.G. Bilo, L.G. Elving, B. Veldman, G. Vervoort
2006 Helsinki, Finland – P-H. Groop, C. Forsblom, M. Saraheimo, L. Thorn
2007 Edinburgh, UK – J.Walker (Minutes from this meeting)
2008 Hannover, Germany – H.Haller, M.Meier, J. Menne
2009 Frascati, Italy – G. Pugliese, F. Pugliese

2010 Poitiers, France – S.Hadjadj (Minutes from this meeting)
2011 Ljubliana, Slovenia – J Zaletel, D Tongrac (Minutes from this meeting)
2012 Dublin, Ireland – H. Holthöfer (Minutes from this meeting)
2013 Castelldefels, Spain – A.M.Castelao (Minutes from this meeting)
2014 London, UK – L. Gnudi (Minutes from this meeting)
2016 Pisa, IT – A. Solini, G. Penno (Minutes from this meeting)
2017 Helsinki, Finland – D. Gordin, M Lassenius, M. Saraheimo, L. Thorn, C.Forsblom (Minutes from this meeting)
2018 Groningen, The Netherlands – H. Lambers (Minutes from this meeting)

1988 Pisa, Italy – U. Di Mario, R. Navalesi, R. Nosadini
1989 Aarhus, Denmark – C.E. Mogensen, J. Sandahl Christiansen,
1990 London, UK – G.C. Viberti
1991 Angers, France – M. Marre
1992 Helsinki, Finland – L. Groop, A. Ekstrand, C. Forsblom, C. Grönhagen-Riska
1993 Athens, Greece – B. Karamanos, P. Kontessis, A. Kofinis
1994 Zwolle, The Netherlands – E. van Ballegooie, H.J.G. Bilo
1995 Heidelberg, Germany – C. Hasslacher, H.P. Kempe
1996 Parma, Italy – A. Gnudi, R. Lugari
1997 Bratislava, Slovakia – P. Pontuch, V. Mojto, S. Kozáková
1998 Rennes, France – J-Y. Poirier, A. Moisan
1999 Gdańsk, Poland – E. Semetkowska-Jurkiewicz, E. Orlowska-Kunikowska

2000 Lund, Sweden – O. Torffvit
2001 County Durham, UK – R. Bilous, S. Marshall
2002 Barcelona, Spain – J.M. Mauri, J.M. Fernández Real, M.T. Gonzáles,
A.M. Castelao, R. Pascual, 2003 Elsinore, Denmark – H-H. Parving, L. Tarnow
2004 Bergamo, Italy – R. Trevisan
2005 Arnhem, The Netherlands – J.H.M. Berden, H.J.G. Bilo, L.G. Elving, B. Veldman, G. Vervoort
2006 Helsinki, Finland – P-H. Groop, C. Forsblom, M. Saraheimo, L. Thorn
2007 Edinburgh, UK – J.Walker (Minutes from this meeting)
2008 Hannover, Germany – H.Haller, M.Meier, J. Menne
2009 Frascati, Italy – G. Pugliese, F. Pugliese

2010 Poitiers, France – S.Hadjadj (Minutes from this meeting)
2011 Ljubliana, Slovenia – J Zaletel, D Tongrac (Minutes from this meeting)
2012 Dublin, Ireland – H. Holthöfer (Minutes from this meeting)
2013 Castelldefels, Spain – A.M.Castelao (Minutes from this meeting)
2014 London, UK – L. Gnudi (Minutes from this meeting)
2016 Pisa, IT – A. Solini, G. Penno (Minutes from this meeting)
2017 Helsinki, Finland – D. Gordin, M Lassenius, M. Saraheimo, L. Thorn, C.Forsblom (Minutes from this meeting)
2018 Groningen, The Netherlands – H. Lambers (Minutes from this meeting)

Workshop Program

Friday, May 24th, 2019

08.00-09.00 : Registration (Hall 21)

09.00-09.15 : Opening Ceremony Sally Marshall, President of EDNSG & Welcome Jessica Zucman Rossi, Director of Cordeliers Research Center 

09:15-10:00 : Ruth Østerby Lecture 

Chair : Sally Marshall 

Per-Henrik Groop. Title TBC

10.00-11.00 :  Session 1 – OP Clinical omics -Predective value for DKD progression and new therapeutic targets 

Chairs :  Ronan Roussel (Paris, France) & Niina Sandholm (Helsinki Finland)

OP 1A – Axon guidance pathway proteins are associated with ESKD and kidney lesions in southwestern American Indians with type 2 diabetes – Saulnier PJ.

OP 1B – Circulating microRNAs point to Axon Guidance Pathway Proteins – Ephrin Family – as major determinants of progression to ESRD in diabetes – Eiichiro S.

OP 1C – Urine Metabolites Predict Rapid Renal Function Decline in Individuals with T1D – Valo E.

OP 1D – Identification of serum metabolites associated with renal impairment: A metabolomics study in Type 1 Diabetes –Tofte N.

11:00-11:30 : Coffee Break and Exhibition 

11:30-13:00
: Session 2 – OP Basic science – hemodynamics, inflammation, fibrosis, regenerative medicine in rodent models              

Chairs : George L. King (Boston MA, USA) & Catherine Godson (Dublin, Ireland)

OP 2A – A new SHIP2 inhibitor enhances insulin sensitivity and attenuates kidney injury in diabetic db/db mice –Polianskyte-Prause Z.

OP 2B – Effect of M-SEC deletion in streptozotocin-induced diabetic mice –Barutta F.

OP 2C – Endothelial ADAM17 deletion protects against diabetic nephropathy – Palau V.

OP 2D – Nox4 versus Nox5: in diabetic kidney disease – Jha JC.

OP 2E – Tankyrases regulate mitochondrial master regulator PGC-1α in the kidney of diabetic db/db mice – Kuusela S.

OP 2F – Matrix metalloproteinase (MMP)-mediated syndecan 4 loss from the endothelial glycocalyx as a therapeutic target in diabetic nephropathy –Ramnath RD.

13.00-14.00 : Lunch

14.00–14.45 : Invited Lecture 1 

Chair : Gabriella Gruden (Turin, Italy)

Merlin C. Thomas – Monash University – Melbourne, Australia

New RAGE in Diabetic Kidney Disease

14.45–16.15 : Session 3 – OP: Kidney X Heart crosstalk in diabetes 

Chairs :  Frederik Persson (Copenhagen, Denmark)

OP 3A – Glomerular Hyperfiltration and All-cause Mortality in Individuals with Type 2 Diabetes: The Renal Insufficiency and Cardiovascular Events (RIACE) Italian Multicentre Study –Pugliese G.

OP 3B – Renal phenotypes associated with major cardiovascular events in patients with type 2 diabetes: an application of joint latent class modeling in the SURDIAGENE cohort – Ragot S.

OP 3C – Short- term response to RAAS inihibition and the risk of cardiovascular events in individuals with type 1 diabetes –Lithovius R. 

OP 3D – Arterial stiffness predicts all-cause mortality in type 1 diabetes – Tynjälä A.

OP 3E – Soluble urokinase plasminogen activator receptor predicts cardiovascular events, kidney function decline, and mortality in patients with type 1 diabetes –Rotbain Curovic V.

OP 3F – Clinical markers at the start of RAAS (renin-angiotensin-aldosterone system) therapy relate to cardiovascular outcomes in type 1 diabetes: A subgroup analysis – Mutter S.

16.15–16.45 Coffee break and exhibition

16.45–17.30 : Invited lecture 2 

Chair: Daniel T. Gordin (Helsinki, Finland)

George L. King – Joslin Diabetes Center, Harvard Medical School – Boston, MA, USA.

Novel lipid targets for therapy in DKD

17.30–18.15 Annual General Meeting of the EDNSG

Saturday, May 25th, 2019

09.00–10.00 Session 4 OP : Cell signaling – Oxidative and inflammatory pathways 

Chairs:  Sanna H Lehtonen (Helsinki, Finland) & Simon Satchell (Bristol, UK) 

OP 4A – Insulin signaling regulates bioenergetics in podocytes – Betin V.

OP 4B – The insulin/IGF axis is critical for podocyte function but partial inhibition of IGF1 signalling is physiologically beneficial- Hurcombe J.

OP 4C – Modulation of alternative splicing: a novel therapeutic strategy in diabetic nephropathy – Oltean S.

OP 4D – Mesenchymal Stem Cells Attenuate Diabetic Kidney Disease through NADPH oxidases Dependent Mechanism – Njeim R.

10.00–11.15 : Session 5 OP: Biomarkers for predicting progression of Diabetic Kidney Disease 

Chairs:  Anna Solini (Pisa, Italy) & Samy Hadjadj (Nantes, France)

OP 5A – Copeptin and renin-angiotensin-aldosterone system (RAAS) activation in long-standing type 1 diabetes (T1D) – Bjornstad P.

OP 5B – AVP gene variants, plasma copeptin and diabetes kidney disease in type 2 diabetes – Velho G.

OP 5C – The utility of plasma concentration of Trimethylamine-N-Oxide in predicting cardiovascular and renal complications in individuals with type 1 diabetes – Winther SA.

OP 5D – Albuminuria and other measures of microvascular dysfunction are associated with worse cognitive performance: The Maastricht Study –Rensma SP.

OP 5E – Prospective association of resting heart rate with rapid renal function decline in Asians with type 2 diabetes- Liu J-J.

11.15–11.45 : Coffee break and exhibition

11.45–12.45 : Poster Sessions and Exhibition

Parallel Poster Session 1: Clinical care of DKD patients – prognostic factors, -omics and clinical interventions 

Chair:  Janaka Karalliedde (London, UK)

PP 1A – Empagliflozin and progression of chronic kidney disease in type 2 diabetes complicated by nephrotic-range proteinuria: insights from the EMPA-REG OUTCOME® trial – Ruggenenti P.

PP 1B – Empagliflozin Improves Kidney Outcomes Irrespective of Control of Blood Pressure, Low-Density Lipoprotein Cholesterol and HbA1c – Cooper ME.

PP 1C – Exposure-Response relationships of dapagliflozin on renal risk markers and adverse events – Koomen JW.

PP 1D – Pulse Wave Velocity is an Independent Risk Factor for Cardiovascular Events, Mortality and Decline in Renal Function in Patients with Type 1 Diabetes – Hansen TW.

PP 1E – Obesity and Vascular Stiffness in People with Type 2 Diabetes –Delles C.

PP 1F – Reduced levels of the anti-ageing hormone Klotho are associated with increased aortic stiffness in patients with diabetic kidney disease – Panagiotou A.

PP 1G – The impact of bacterial infections on incident cardiovascular disease in patients with type 1 diabetes – Simonsen R.

PP 1H – Morphological and vascular kidney indexes in type 2 diabetic individuals with different Diabetic Kidney Disease (DKD) phenotypes – 

Garofolo M.

PP 1I – Secular trends of chronic kidney disease in people with type 1 and type 2 diabetes in developing countries (2005–2017): The International Diabetes Management and Practices Study (IDMPS) – Mbanya JC.

PP 1J – Renal NGAL expression and urinary NGAL Excretion Remain Elevated Following Intensive Weight Loss and Medical Therapy for Experimental Diabetic Kidney Disease – Docherty N.

PP 1K – Early and discordant changes in urinary albumin and NGAL excretion when gastric bypass surgery is added to best medical therapy for type 2 diabetic kidney disease – Martin WP.

PP 1L – Association between individual cholesterol and albuminuria response and exposure to atorvastatin or rosuvastatin – Kroonen M.YAM.

Parallel Poster Session 2: Basic science – hemodynamics, inflammation, fibrosis and regenerative medicine 

Chair : Mark Cooper (Melbourne, Australia)

PP 2A – An omics approach to characterise murine podocyte networks exposed to a diabetic environment – Graham M.

PP 2B – Transcriptome and proteome of extracellular vesicles derived from cellular targets of diabetic kidney disease – Barreiro K.

PP 2C – Dapagliflozin improves the urinary CKD273 proteomic score when added to renin-angiotensin blockade in patients with type 2 diabetes and nephropathy – Klessen Eickhoff M.

PP 2D – Whole Exome Sequencing-Based Gene Discovery in Families Enriched for Rapid Progression of Renal Decline in Diabetes – Pezzolesi MG.

PP 2E – Heritability of glomerular structure in type 2 diabetes – Looker H.

PP 2F – Cellular origin and microRNA content of plasma extracellular vesicles in diabetic nephropathy – Uil M.

PP 2G – LXR/mTOR/Nox4 Signaling Axes: Novel Therapeutic Targets in Diabetic Nephropathy – Al Khansa S.

PP 2H – IGFBP-1 is reduced in human and mouse diabetic glomeruli and regulates β1-integrin/FAK signaling in human podocytes –Lay AC.

PP 2I – Diabetic conditions enhance the phosphorylation of PACSIN2/syndapin II in podocytes – Bouslama R.

PP 2J – Induced endothelial expression of podocyte specific Retinoic acid receptor responder 1 (Rarres1) in Glomerular Nephritis (GN) accelerates renal injury – Möller-Hackbarth K.

PP 2K – A Novel Heparanase Inhibitor Protects Glomerular Endothelial Glycocalyx During Diabetes Mellitus – Gamez M.

PP 2L – Novel alternative splicing events in the diabetic endothelium – Stevens M.

12.45–13.45 Lunch

13.45–14.30 Invited Lecture 3 – Chair: Ronan Roussel (Paris, France) 

Denis Fouque -University Claude Bernard Lyon 1, Edouard HERRIOT Hospital – Lyon, France 

 Nutritional care in chronic kidney disease in 2019

14.30 – 15.45 Session 6 OP: Therapeutics – pharmaceutical interventions and focus on SGLT2 

Chairs:  Hiddo Lambers Heerspink (Groningen, The Netherlands) & Merlin Thomas (Melbourne, Australia)

OP 6A – Dapagliflozin reduces measured GFR by reducing renal efferent arteriolar resistance in type 2 diabetes – V. Raalte D.

OP 6B – Relationship between renal capacities to reabsorb glucose and kidney disease in patients with diabetes – Matar O.

OP 6C – Effects of Dapagliflozin on Volume Markers When Added to Renin-Angiotensin Blockade in Patients with Type 2 Diabetes and Elevated Albuminuria – Dekkers CCJ.

OP 6D – The effects of dapagliflozin on urinary metabolites reflecting renal mitochondrial function in patients with type 2 diabetes – Pena M. 

OP 6E – Prediction and validation of the effects of exenatide on progression of kidney disease in type 2 diabetes – Idzerda NMA.

15.45 –16.15 Closing session

Best Communications Prizes

Closing Remarks and coffee to go

Friday, May 24th, 2019 

08.00–09.00 : Registration (Hall 21)

09.00–09.15 : Opening Ceremony – Sally Marshall, President of the EDNSG & Welcome – Jessica Zucman Rossi, Director of Cordeliers Research Center

09.15–10.00 : Ruth Østerby Lecture 

Chair: Sally Marshall

Per-Henrik Groop. Title TBC

10.00–11.00 : Session 1 OP: Clinical omics – Predictive value for DKD progression and new therapeutic targets

Chairs:  Ronan Roussel (Paris, France) & Niina Sandholm (Helsinki Finland)

OP 1A – Axon guidance pathway proteins are associated with ESKD and kidney lesions in southwestern American Indians with type 2  diabetes – Saulnier PJ.

OP 1B – Circulating microRNAs point to Axon Guidance Pathway Proteins – Ephrin Family – as major determinants of progression to ESRD in diabetes – Eiichiro S.

OP 1C – Urine Metabolites Predict Rapid Renal Function Decline in Individuals with T1D – Valo E.

OP 1D – Identification of serum metabolites associated with renal impairment: A metabolomics study in Type 1 Diabetes – Tofte N.

11.00–11.30 : Coffee and exhibition

11.30-13.00 : Session 2 : OP: Basic science – hemodynamics, inflammation, fibrosis, regenerative medicine in rodent models

Chairs : George L. King (Boston MA, USA) & Catherine Godson (Dublin, Ireland)

OP 2A – A new SHIP2 inhibitor enhances insulin sensitivity and attenuates kidney injury in diabetic db/db mice – Polianskyte-Prause Z.

OP 2B – Effect of M-SEC deletion in streptozotocin-induced diabetic mice – Barutta F.

OP 2C – Endothelial ADAM17 deletion protects against diabetic nephropathy – Palau V.

OP 2D – Nox4 versus Nox5: in diabetic kidney disease – Jha JC.

OP 2E – Tankyrases regulate mitochondrial master regulator PGC-1α in the kidney of diabetic db/db mice – Kuusela S.

OP 2F – Matrix metalloproteinase (MMP)-mediated syndecan 4 loss from the endothelial glycocalyx as a therapeutic target in diabetic nephropathy – Ramnath RD.

13.00–14.00 : Lunch

14.00–14.45 : Invited Lecture 1 

Chair: Gabriella Gruden (Turin, Italy)

Merlin C. Thomas – Monash University – Melbourne, Australia. New RAGE in Diabetic Kidney Disease

14.45–16.15 : Session 3 OP : Kidney X Heart crosstalk in diabetes

Chairs:  Frederik Persson (Copenhagen, Denmark)

OP 3A – Glomerular Hyperfiltration and All-cause Mortality in Individuals with Type 2 Diabetes: The Renal Insufficiency and Cardiovascular Events (RIACE) Italian Multicentre Study – Pugliese G.

OP 3B – Renal phenotypes associated with major cardiovascular events in patients with type 2 diabetes: an application of joint latent class modeling in the SURDIAGENE cohort – Ragot S.

OP 3C – Short-term response to RAAS inhibition and the risk of cardiovascular events in individuals with type 1 diabetes – Lithovius R. 

OP 3D – Arterial stiffness predicts all-cause mortality in type 1 diabetes – Tynjälä A.

OP 3E – Soluble urokinase plasminogen activator receptor predicts cardiovascular events, kidney function decline, and mortality in patients with type 1 diabetes – Rotbain Curovic V.

OP 3F – Clinical markers at the start of RAAS (renin-angiotensin-aldosterone system) therapy relate to cardiovascular outcomes in type 1 diabetes: A subgroup analysis – Mutter S.

16.15–16.45 : Coffee break and exhibition

16.45–17.30 : Invited lecture 2 

Chair: Daniel T. Gordin (Helsinki, Finland)

George L. King – Joslin Diabetes Center, Harvard Medical School – Boston, MA, USA

Novel lipid targets for therapy in DKD 

17.30–18.15 Annual General Meeting of the EDNSG

             Saturday, May 25th, 2019

09.00–10.00 : Session 4 : OP: Cell signaling – Oxidative and inflammatory pathways 

Chairs:  Sanna H Lehtonen (Helsinki, Finland) & Simon Satchell (Bristol, UK) 

OP 4A – Insulin signaling regulates bioenergetics in podocytes – Betin V.

OP 4B – The insulin/IGF axis is critical for podocyte function but partial inhibition of IGF1 signalling is physiologically beneficial – Hurcombe J.

OP 4C – Modulation of alternative splicing: a novel therapeutic strategy in diabetic nephropathy – Oltean S.

OP 4D – Mesenchymal Stem Cells Attenuate Diabetic Kidney Disease through NADPH oxidases Dependent Mechanism – Njeim R.

10.00–11.15 : Session 5 OP : Biomarkers for predicting progression of Diabetic Kidney Disease 

Chairs:  Anna Solini (Pisa, Italy) & Samy Hadjadj (Nantes, France)

OP 5A – Copeptin and renin-angiotensin-aldosterone system (RAAS) activation in long-standing type 1 diabetes (T1D) – Bjornstad P.

OP 5B – AVP gene variants, plasma copeptin and diabetes kidney disease in type 2 diabetes – Velho G.

OP 5C – The utility of plasma concentration of Trimethylamine-N-Oxide in predicting cardiovascular and renal complications in individuals with type 1 diabetes – Winther SA.

OP 5D – Albuminuria and other measures of microvascular dysfunction are associated with worse cognitive performance: The Maastricht Study- Rensma SP.

OP 5E –  Prospective association of resting heart rate with rapid renal function decline in Asians with type 2 diabetes – Liu J-J.

11.15–11.45 Coffee break and exhibition

11.45–12.45 Poster sessions and exhibition

Parallel Poster Session 1 : Clinical care of DKD patients – prognostic factors, -omics and clinical interventions 

Chair:  Janaka Karalliedde (London, UK)

PP 1A – Empagliflozin and progression of chronic kidney disease in type 2 diabetes complicated by nephrotic-range proteinuria: insights from the EMPA-REG OUTCOME® trial – Ruggenenti P.

PP 1B – Empagliflozin Improves Kidney Outcomes Irrespective of Control of Blood Pressure, Low-Density Lipoprotein Cholesterol and HbA1c – Cooper ME.

PP 1C – Exposure-Response relationships of dapagliflozin on renal risk markers and adverse events – Koomen JW.

PP 1D – Pulse Wave Velocity is an Independent Risk Factor for Cardiovascular Events, Mortality and Decline in Renal Function in Patients with Type 1 Diabetes – Hansen TW.

PP 1E – Obesity and Vascular Stiffness in People with Type 2 Diabetes –Delles C.

PP 1F – Reduced levels of the anti-ageing hormone Klotho are associated with increased aortic stiffness in patients with diabetic kidney disease – Panagiotou A.

PP 1G – The impact of bacterial infections on incident cardiovascular disease in patients with type 1 diabetes – Simonsen R.

PP 1H – Morphological and vascular kidney indexes in type 2 diabetic individuals with different Diabetic Kidney Disease (DKD) phenotypes – Garofolo M.

PP 1I – Secular trends of chronic kidney disease in people with type 1 and type 2 diabetes in developing countries (2005–2017): The International Diabetes Management and Practices Study (IDMPS) – Mbanya JC.

PP 1J – Renal NGAL expression and urinary NGAL Excretion Remain Elevated Following Intensive Weight Loss and Medical Therapy for Experimental Diabetic Kidney Disease-Docherty N.

PP 1K – Early and discordant changes in urinary albumin and NGAL excretion when gastric bypass surgery is added to best medical therapy for type 2 diabetic kidney disease –Martin WP.

PP 1L – Association between individual cholesterol and albuminuria response and exposure to atorvastatin or rosuvastatin – Kroonen M.YAM.

Parallel Poster Session 2 : Basic science – hemodynamics, inflammation, fibrosis and regenerative medicine 

Chair: Mark Cooper (Melbourne, Australia)

PP 2A – An omics approach to characterise murine podocyte networks exposed to a diabetic environment – Graham M.

PP 2B – Transcriptome and proteome of extracellular vesicles derived from cellular targets of diabetic kidney disease – Barreiro K.

PP 2C – Dapagliflozin improves the urinary CKD273 proteomic score when added to renin-angiotensin blockade in patients with type 2 diabetes and nephropathy – Klessen Eickhoff M.

PP 2D – Whole Exome Sequencing-Based Gene Discovery in Families Enriched for Rapid Progression of Renal Decline in Diabetes –Pezzolesi MG.

PP 2E – Heritability of glomerular structure in type 2 diabetes –  Looker H.

PP 2F – Cellular origin and microRNA content of plasma extracellular vesicles in diabetic nephropathy-   Uil M.

PP 2G – LXR/mTOR/Nox4 Signaling Axes: Novel Therapeutic Targets in Diabetic Nephropathy – Al Khansa S..

PP 2H – IGFBP-1 is reduced in human and mouse diabetic glomeruli and regulates β1-integrin/FAK signaling in human podocytes –Lay AC.

PP 2I – Diabetic conditions enhance the phosphorylation of PACSIN2/syndapin II in podocytes – Bouslama R.

PP 2J – Induced endothelial expression of podocyte specific Retinoic acid receptor responder 1 (Rarres1) in Glomerular Nephritis (GN) accelerates renal injury – Möller-Hackbarth K.

PP 2K – A Novel Heparanase Inhibitor Protects Glomerular Endothelial Glycocalyx During Diabetes Mellitus – Gamez M.

PP 2L – Novel alternative splicing events in the diabetic endothelium – Stevens M.

 12.45–13.45 : Lunch

13.45–14.30 : Invited Lecture 3 

Chair: Ronan Roussel (Paris, France) 

Denis Fouque – University Claude Bernard Lyon 1, Edouard HERRIOT Hospital – Lyon, France 

Nutritional care in chronic kidney disease in 2019

14.30 – 15.45 : Session 6 OP : Therapeutics – pharmaceutical interventions and focus on SGLT2 

Chairs: Hiddo Lambers Heerspink (Groningen, The Netherlands) & Merlin Thomas (Melbourne, Australia)

OP 6A – Dapagliflozin reduces measured GFR by reducing renal efferent arteriolar resistance in type 2 diabetes – V. Raalte D.

OP 6B – Relationship between renal capacities to reabsorb glucose and kidney disease in patients with diabetes – Matar O.

OP 6C – Effects of Dapagliflozin on Volume Markers When Added to Renin-Angiotensin Blockade in Patients with Type 2 Diabetes and Elevated Albuminuria –       Dekkers CCJ.

OP 6D – The effects of dapagliflozin on urinary metabolites reflecting renal mitochondrial function in patients with type 2 diabetes – Pena M. 

OP 6E – Prediction and validation of the effects of exenatide on progression of kidney disease in type 2 diabetes – Idzerda NMA.

15.45–16.15 : Closing session

Best Communications Prizes

Closing Remarks and coffee to go

Abstracts

Authors will be informed on acceptance of their abstract by the end of February.  All submitted abstracts will be published in the abstact book unless the author has advised not to do so.

The presenting author must register as an active participant at the conference after acceptance of an abstract. EDNSG 2019 reserves the right to exclude any abstract that is not followed by the speaker registration after notification of acceptance.

Presentation format

 All presentations should be in PowerPoint format and PC compatible. The projection format will be 16:9.   Slides must have a portrait format (vertical format).  PowerPoint 2016 and previous versions are accepted. Save your file with a .pptx extension for a better compatibility.  Click here to download the speaker guidelines. 

All speakers are required to send their PPT presentation by email at the following address before Monday, May 20th to Monica Galli: ednsg@clq-group.com

Posters dimensions 

Posters are in portrait format. Format A0 (width: 84,1 cm/height: 118,9 cm).

Authors will be informed on acceptance of their abstract by the end of February.  All submitted abstracts will be published in the abstact book unless the author has advised not to do so.

The presenting author must register as an active participant at the conference after acceptance of an abstract. EDNSG 2019 reserves the right to exclude any abstract that is not followed by the speaker registration after notification of acceptance.

Presentation format

 All presentations should be in PowerPoint format and PC compatible. The projection format will be 16:9.   Slides must have a portrait format (vertical format).  PowerPoint 2016 and previous versions are accepted. Save your file with a .pptx extension for a better compatibility. Click here to download the speaker guidelines.

All speakers are required to send their PPT presentation by email at the following address before Monday, May 20th to Monica Galli : ednsg@clq-group.com

Posters dimensions 

Posters are in portrait format. Format A0 (width: 84,1 cm/height: 118,9 cm)

Travel Grant guidelines

1. History
The travel grants were decided when the EDNSG had a special amount of money from the 2005 Papendahl meeting. It was thus decided to promote the attendance of young scientists and physicians to the Group by offering some travel grants.

2. Conditions of application
Candidates can apply for this travel grant at the occasion of the submission of the abstract for the next coming EDNSG meeting. Travel grant deadline corresponds to abstract deadline.

Applicant must preferably be aged below 35 years at the day of the opening of the corresponding EDNSG Annual meeting.

Application must be sent in a specific email including birth date, place of work, title of the submitted abstract and indication of the year(s) of previous travel grants selection.

The number of travel grants recipients for each working group cannot exceed two.

3. Payment
The travel grant only consists of a reimbursement of the expenses needed to attend the EDNSG meeting. No advanced payment is allowed. The maximum amount of travel grant is 500 euros. Travel grant recipients must then provide some invoices to justify their expenses.

1. History
The travel grants were decided when the EDNSG had a special amount of money from the 2005 Papendahl meeting. It was thus decided to promote the attendance of young scientists and physicians to the Group by offering some travel grants.

2. Conditions of application
Candidates can apply for this travel grant at the occasion of the submission of the abstract for the next coming EDNSG meeting. Travel grant deadline corresponds to abstract deadline.

Applicant must preferably be aged below 35 years at the day of the opening of the corresponding EDNSG Annual meeting.

 

 

Application must be sent in a specific email including birth date, place of work, title of the submitted abstract and indication of the year(s) of previous travel grants selection.

The number of travel grants recipients for each working group cannot exceed two.

3. Payment
The travel grant only consists of a reimbursement of the expenses needed to attend the EDNSG meeting. No advanced payment is allowed. The maximum amount of travel grant is 500 euros. Travel grant recipients must then provide some invoices to justify their expenses.

Registration

Online registration opening: Monday, March 4th, 2019

Online registration deadline: Monday, April 15th, 2019

The registration fee for EDNSG member includes:

  • Access to the meeting (abstact book, final program)
  • Access to social events
  • Coffee breaks and lunches
  •  Hotel in twin room

If you are not a EDNSG member and you would like to participate, please contact ednsg@clq-group.com

Online registration opening: Monday, March 4th 2019

Online registration deadline: Monday, April 15th  2019

The registration fee for EDNSG member includes:

  • Access to the meeting (abstact book, final program)
  • Access to social events
  • Coffee breaks and lunches
  • Hotel reservation up to 2 nights in twin room

If you are not a EDNSG member and you would like to participate, please contact ednsg@clq-group.com

 

cordeliers

Venue

Location

Cordeliers Research Center 
15 rue de l’Ecole de Médecine
75006 Paris – France

  • Station Odeon  –  Line 4 ou 10
  • RER B –  Stations Saint-Michel or Luxembourg
  • RER C – Station Saint-Michel
  • Bus (stops Rue des Ecoles or Odeon) – Line 38, 27, 58

From Charles de Gaulle airport

  • RER B – Direction Saint-Rémy-les-Chevreuse, Station Saint Michel (5 minutes walk) or RER B – Station Saint Michel and line 4  (direction Marie de Montrouge)- station Odeon

From Orly airport

Orly bus- Station Denfert Rochereau and take line 4, direction Porte de Clignancourt- Station Odeon

Contact
for more information

Coordination & Program   

            EL BOUSTANY Ray               

  ray_boustany@hotmail.com

Coordination & Registration 

GALLI Monica
+33 1 44 64 14 89
ednsg@clq-group.com

Contact
for more information

Coordination & Program                                         

EL BOUSTANY Ray
ray_boustany@hotmail.com

Coordination & Registration 

GALLI Monica
 +33 1 44 64 14 89
 ednsg@clq-group.com 

Powered by Colloqium – 2019 – Legal notice

Fermer le menu